COVID-19 Immunogenicity of a Third Dose of mRNA-1273 Vaccine Among Cancer Patients
Investigators will evaluate the immunogenicity of a third dose of mRNA-1273 SARS-CoV-2 vaccine among cancer patients receiving the recommended third vaccine dose
Checked against the public recordLast updated Apr 14, 2023 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Interventions being studied
- Biological: mRNA-1273
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * At least 18 years of age * Is a cancer patient enrolled in the Cancer Patient Immune Response to COVID-19 Vaccine study (a basic science study) MCC 21138 or who has completed the two mRNA-1273 vaccine series prior to March 31, 2021. * Understands, agrees and is able to comply with the study procedures and provides written informed consent. * Has no known or suspected allergy or history of anaphylaxis, urticaria, or other significant adverse reactions to the vaccine or its excipients. * Has not received more or less than 2 doses of mRNA-1273 vaccine Exclusion Criteria: * Participants who will not return for the third vaccine dose
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Moffitt Cancer CenterTampa, Florida
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Apr 14, 2023. Always confirm current availability with the study team.